.png){kind=logo}
This funding opportunity addresses systemic and structural factors that impede or facilitate the pre-exposure prophylaxis (PrEP) uptake and persistence among people who use substances in the U.S. and worldwide. Particular emphasis should be placed on strategies designed to benefit populations disproportionately affected by substance use and human immunodeficiency viruses (HIV). Read more here.
RFA-DA-26-003 for R01 applications
RFA-DA-26-004 for R34 applications
Applications Due March 12, 2025
The Notice of Special Interest (NOSI) seeks to fill scientific gaps needed to (a) inform HBV cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts; and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a cure in HIV and HBV co-infected individuals.
First Available Due Date: September 05, 2022
Expiration Date: May 08, 2025
The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.
First Available due date: September 7, 2022
Expiration Date: May 8, 2025